What Recormon Treats: Main Uses and Benefits

Recormon is commonly used across therapeutic domains where additional symptomatic support is needed, focusing on symptomatic anemia to ease the overall symptom burden. The overall benefit may assist with managing symptoms that create noticeable physiological strain.

The medication is primarily applied in three clinical scenarios: to address anemia in chronic kidney disease in adults and children, to manage anemia related to myelosuppressive chemotherapy for certain cancer patients, and for specialized uses like assisting with autologous blood donation before major surgery.

This support is relevant for managing debilitating symptoms linked to low red blood cell counts, such as chronic fatigue, weakness, and shortness of breath. It contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

---

Quick Fact: Support for Anemia Symptoms

Property	Description
Symptom Focus	Fatigue, weakness, reduced physical function, shortness of breath.
Primary Context	Anemia associated with Chronic Kidney Disease or Chemotherapy.
Core Benefit	Plays a role in managing the need for red blood cell transfusions.
Patient Goal	Supports patients in improving day-to-day comfort and coping more steadily with symptom fluctuations.

Who Can and Cannot Use Recormon?

This section details the official population eligibility and non-eligibility rules for Recormon (Epoetin Beta) as defined in regulatory labeling.

---

Populations Explicitly Allowed

Recormon is approved for use in specific populations with symptomatic anemia:

• Adults with anemia related to Chronic Kidney Disease (CKD) or chemotherapy for non-myeloid malignancies.
• Adults undergoing autologous blood pre-donation for major surgery (only if moderately anemic).
• Premature infants with a birth weight of 750 to 1500 grams and a gestational age of less than 34 weeks.

---

Formal Contraindications (Must Not Use)

Recormon is formally prohibited for the following groups:

Contraindication	Description
Uncontrolled Hypertension	Patients whose high blood pressure cannot be adequately managed by medicine.
Hypersensitivity	Known allergy to Epoetin Beta or any ingredient in the product.
Prior PRCA	History of Pure Red Cell Aplasia following treatment with any erythropoietic agent.
Autologous Donation Risk	History of stroke, myocardial infarction, or high risk of DVT within the month prior to treatment (specific to this indication).

---

Conditional Use and Restrictions

Use requires caution in patients with conditions like chronic liver failure or epilepsy. The medicine is not indicated for children in the chemotherapy or autologous donation settings. Use in pregnancy and during lactation requires a physician's careful benefit-risk assessment due to limited human data.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Recormon (Epoetin Beta) by the absence of classical pharmacokinetic (PK) interactions and the presence of a few clinically relevant pharmacodynamic (PD) interactions. As a recombinant protein, Epoetin Beta is not metabolized by the Cytochrome P450 (CYP) enzyme system and has no documented interactions with drug transport proteins.

Documented Interaction Patterns

The regulatory data confirms that the most significant interactions are tied to the drug’s effect on blood components and pressure, requiring specific adjustments under certain conditions:

• Angiotensin-Converting Enzyme (ACE) Inhibitors: Co-administration may increase the risk of hyperkalemia (elevated potassium levels), which is a key consideration for patients with chronic renal failure.
• Anticoagulants (e.g., Heparin): For patients undergoing hemodialysis, the increase in red blood cell count induced by Recormon necessitates a potential increase in the dose of anticoagulant to prevent clotting in the dialysis circuit.
• Interferon and Ribavirin: Co-use of Epoetin Beta with this specific antiviral combination has been formally associated with the development of Pure Red Cell Aplasia (PRCA), a type of severe anemia.

Interaction Restrictions

Interaction Type	Status in Regulatory Documents
Contraindicated Combinations	None listed based on classical drug-drug interaction risk.
Timing Requirements	None documented for separating administration from other medicines.

Recormon is a recombinant human erythropoietin (r-HuEPO), functioning as a cytokine agonist. Its primary biological target is the Erythropoietin Receptor (EPOR), a transmembrane receptor expressed predominantly on the surface of committed erythroid progenitor cells in the bone marrow.

The drug mimics the action of endogenous erythropoietin, binding to two EPOR monomers to induce receptor dimerization. This dimerization causes the activation of the Janus Kinase 2 (JAK2) enzyme, which is constitutively associated with the intracellular domains of the receptor. Activated JAK2 then initiates a molecular cascade by phosphorylating key intracellular substrates and the receptor itself.

The major downstream pathway modulated is the JAK2-STAT5 signaling cascade. Phosphorylation leads to the activation and nuclear translocation of Signal Transducer and Activator of Transcription 5 (STAT5). Once in the nucleus, STAT5 upregulates the transcription of genes critical for cell survival, proliferation, and differentiation of erythroid precursors. This intracellular mechanism overcomes the programmed death (apoptosis) of progenitor cells and accelerates their maturation process, resulting in the system-level physiological consequence of increased release of reticulocytes and mature erythrocytes from the bone marrow into the peripheral circulation.

The administration of Recormon (Epoetin Beta) is strictly governed by a procedural framework detailed in regulatory documents. The medication is supplied as a solution for injection and is approved for use via subcutaneous (SC) or intravenous (IV) routes. The SC route is commonly used for patients not on dialysis, while the IV route is often preferred via a vascular access site at the end of a dialysis session. IV injections have a specific administration rate, typically delivered slowly over approximately two minutes.

The overall use protocol is separated into a higher-dose Correction Phase and a long-term Maintenance Phase. Dosage is weight-based, calculated and prescribed in International Units (IU) per kilogram of body weight. For Chronic Kidney Disease (CKD) anemia, the SC Correction Phase starting dose is commonly 3 x 20 IU/kg per week, whereas the IV starting dose is typically higher. For chemotherapy-induced anemia, initial doses may be up to 30,000 IU per week.

Administration Scope	Official Usage Rule
Dosing Frequency	Ranges from three times weekly (Correction Phase) to once weekly or once every two weeks (Maintenance Phase).
Dose Adjustment	Must not be increased or decreased more frequently than every four weeks.
Hemoglobin Target	Therapy aims to maintain Hemoglobin (Hb) within a target regulatory range, such as 10 to 12 g/dL.

Special procedural conditions apply, including the official recommendation for the first dose to be administered under medical supervision. Furthermore, official dosing acknowledges that pediatric CKD patients may require higher average doses than adults, and the product is intended for single use only.

Research Evidence / Overview of Studies for Recormon

---

Evidence for Anemia in Chronic Kidney Disease (CKD)

The research for Epoetin Beta includes Randomized Controlled Trials (RCTs) and Systematic Reviews for patients with chronic kidney failure. Studies were observed in populations of adults and children, including those on dialysis and those with pre-dialysis disease. Researchers primarily monitored outcomes such as the maintenance of Hemoglobin (Hb) levels and changes in Red Blood Cell (RBC) transfusion requirements.

Findings show patterns related to transfusion requirements across studies. However, evidence is limited concerning the long-term impact on overall survival or patient-reported perceived discomfort. Research was associated with an increased rate of cardiovascular outcomes when aiming for very high Hb targets, leading to specific research protocols focused on lower Hb targets.

---

Evidence for Anemia Related to Chemotherapy

The research for anemia related to chemotherapy is built upon Phase III Randomized, Double-blind, Placebo-Controlled Trials. These studies were evaluated in adults with specific non-myeloid cancers undergoing myelosuppressive treatment. Outcomes research examined included the proportion of patients requiring RBC transfusions and patient-reported outcomes related to daily functioning or activity level.

Studies examined the need for transfusions between the treated groups and those receiving a placebo, and research describes short-term changes in Hb levels. Evidence is limited concerning the optimal Hb target in the cancer setting, as some research suggests an association with oncologic outcomes. Follow-up durations were limited primarily to the active treatment period.

---

Evidence for Assisting Autologous Blood Donation

Studies related to autologous blood donation (ABD) were evaluated in patients planning to donate their own blood before major elective surgery. Outcomes research examined included the total volume or units of blood collected and resulting changes in Hb and Hematocrit levels.

Studies reported measurements showing changes in the total volume of blood collected. However, research concerning non-autologous (donor) blood transfusions post-surgery was observed in some studies but with findings that varied across studies in the scientific literature.

---

Key Evidence Gaps and Scientific Uncertainty

The research framework, while extensive in describing hematologic changes, presents areas where certainty remains low. A major gap lies in research consistently demonstrating positive patterns for non-hematologic outcomes, such as extended overall survival. Comparative evidence is lacking for certain patient subgroups, and data for populations like pregnant women remain insufficient.

Common questions about Recormon (FAQ)

---

Q: What is Recormon and how does it work?

The official labeling indicates that Recormon is a prescription medication indicated for the treatment of certain types of anemia, often associated with chronic kidney disease. It contains epoetin beta, which is a recombinant human erythropoietin. This substance acts to stimulate the production of red blood cells in the bone marrow, aiming to raise and maintain hemoglobin levels.

---

Q: Does Recormon cause pain at the injection site?

As with any injection, some patients may experience temporary pain, redness, or bruising at the site where Recormon is administered. Clinical trials suggest that such localized reactions are generally mild. If you experience severe or prolonged discomfort, it is advisable to consult your healthcare provider.

---

Q: Can I travel while undergoing treatment with Recormon?

Treatment with Recormon should be part of a consistent medical plan. Traveling is possible, but planning is necessary to ensure the medication is stored correctly (usually requiring refrigeration) and that your scheduled injection and monitoring visits are maintained. It is important to discuss any travel plans with your healthcare provider to confirm they are safe and consistent with your treatment schedule.

---

Q: What should I do if I miss a scheduled dose of Recormon?

If a dose of Recormon is missed, you should not attempt to adjust your next dose or self-administer the missed dose without guidance. The recommended course of action depends on your individual treatment schedule and condition. Contact your doctor or a qualified healthcare professional immediately for specific advice on how to proceed.

How to Store and Dispose of Recormon (Epoetin Beta)

Recormon must be stored under strict conditions to preserve its integrity. The required storage temperature is in a refrigerator between 2 C and 8 C. The product must not be frozen. To ensure protection from light, the pre-filled syringe or vial must be kept in the original outer carton.

For patient safety, the medication must be stored out of the sight and reach of children.

Recormon may be kept at room temperature (not above 25 C) for a single period of up to 3 days, after which it must be discarded.

Used syringes and needles, which are for single use, must be disposed of immediately in a puncture-proof container.

Unused product and waste material must not be discarded in household waste or wastewater; disposal must comply with local regulatory requirements for pharmaceutical waste.